Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma

NCT01582269 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01582269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01582269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
April 26, 2012
Completion date
October 10, 2024
Enrollment
158 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma